Cargando…
Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review
Topical treatment plays a crucial role in psoriasis management, with non-adherence being a major barrier to treatment success. The fixed-dose combination of calcipotriol (CAL) and betamethasone dipropionate (BDP) represents the first-line choice in topical psoriasis treatment. A CAL/BDP cream based...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539254/ https://www.ncbi.nlm.nih.gov/pubmed/37740858 http://dx.doi.org/10.1007/s13555-023-01003-0 |
_version_ | 1785113458714345472 |
---|---|
author | Torres, Tiago Galván, Jordi Crutchley, Nigel Praestegaard, Morten Iversen, Lars Gisondi, Paolo Carrascosa, José Manuel Halioua, Bruno Bewley, Anthony Pinter, Andreas |
author_facet | Torres, Tiago Galván, Jordi Crutchley, Nigel Praestegaard, Morten Iversen, Lars Gisondi, Paolo Carrascosa, José Manuel Halioua, Bruno Bewley, Anthony Pinter, Andreas |
author_sort | Torres, Tiago |
collection | PubMed |
description | Topical treatment plays a crucial role in psoriasis management, with non-adherence being a major barrier to treatment success. The fixed-dose combination of calcipotriol (CAL) and betamethasone dipropionate (BDP) represents the first-line choice in topical psoriasis treatment. A CAL/BDP cream based on polyaphron dispersion (PAD) Technology has emerged as a novel formulation for a more convenient topical treatment of psoriasis. This article aims to summarize the most relevant published evidence about CAL/BDP PAD-cream and its underlying PAD Technology. The PAD Technology enables CAL and BDP stability in an aqueous cream through a multimolecular shell structure, as well as it increases the penetration of both active ingredients into the epidermis and dermis. This technology also demonstrated to increase the cosmetic acceptability and to provide the desirable sensory properties for a topical psoriasis treatment. Two phase III clinical trials have been conducted so far with CAL/BDP PAD-cream. Findings from both trials revealed high efficacy with a fast onset of action, a favourable safety and tolerability profile and convenience for CAL/BDP PAD-cream compared to CAL/BDP gel. In the trial including patients with psoriasis affecting the scalp (MC2-01-C7), results support the use of CAL/BDP PAD-cream in scalp psoriasis. An anchored matching-adjusted indirect comparison (MAIC) was conducted to compare CAL/BDP PAD-cream and CAL/BDP foam, as both products had been previously compared to CAL/BDP gel. CAL/BDP PAD-cream and CAL/BDP foam showed equivalent efficacy and quality of life at their recommended treatment duration, whereas greater treatment satisfaction for CAL/BDP PAD-cream was found after one week of treatment. Overall, the high patient acceptability and treatment satisfaction observed with CAL/BDP PAD-cream in clinical trials may lead to improved adherence and hence higher efficacy in clinical practice. |
format | Online Article Text |
id | pubmed-10539254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-105392542023-09-30 Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review Torres, Tiago Galván, Jordi Crutchley, Nigel Praestegaard, Morten Iversen, Lars Gisondi, Paolo Carrascosa, José Manuel Halioua, Bruno Bewley, Anthony Pinter, Andreas Dermatol Ther (Heidelb) Review Topical treatment plays a crucial role in psoriasis management, with non-adherence being a major barrier to treatment success. The fixed-dose combination of calcipotriol (CAL) and betamethasone dipropionate (BDP) represents the first-line choice in topical psoriasis treatment. A CAL/BDP cream based on polyaphron dispersion (PAD) Technology has emerged as a novel formulation for a more convenient topical treatment of psoriasis. This article aims to summarize the most relevant published evidence about CAL/BDP PAD-cream and its underlying PAD Technology. The PAD Technology enables CAL and BDP stability in an aqueous cream through a multimolecular shell structure, as well as it increases the penetration of both active ingredients into the epidermis and dermis. This technology also demonstrated to increase the cosmetic acceptability and to provide the desirable sensory properties for a topical psoriasis treatment. Two phase III clinical trials have been conducted so far with CAL/BDP PAD-cream. Findings from both trials revealed high efficacy with a fast onset of action, a favourable safety and tolerability profile and convenience for CAL/BDP PAD-cream compared to CAL/BDP gel. In the trial including patients with psoriasis affecting the scalp (MC2-01-C7), results support the use of CAL/BDP PAD-cream in scalp psoriasis. An anchored matching-adjusted indirect comparison (MAIC) was conducted to compare CAL/BDP PAD-cream and CAL/BDP foam, as both products had been previously compared to CAL/BDP gel. CAL/BDP PAD-cream and CAL/BDP foam showed equivalent efficacy and quality of life at their recommended treatment duration, whereas greater treatment satisfaction for CAL/BDP PAD-cream was found after one week of treatment. Overall, the high patient acceptability and treatment satisfaction observed with CAL/BDP PAD-cream in clinical trials may lead to improved adherence and hence higher efficacy in clinical practice. Springer Healthcare 2023-09-23 /pmc/articles/PMC10539254/ /pubmed/37740858 http://dx.doi.org/10.1007/s13555-023-01003-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Torres, Tiago Galván, Jordi Crutchley, Nigel Praestegaard, Morten Iversen, Lars Gisondi, Paolo Carrascosa, José Manuel Halioua, Bruno Bewley, Anthony Pinter, Andreas Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review |
title | Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review |
title_full | Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review |
title_fullStr | Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review |
title_full_unstemmed | Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review |
title_short | Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review |
title_sort | calcipotriol and betamethasone dipropionate cream based on pad technology for the treatment of plaque psoriasis: a narrative review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539254/ https://www.ncbi.nlm.nih.gov/pubmed/37740858 http://dx.doi.org/10.1007/s13555-023-01003-0 |
work_keys_str_mv | AT torrestiago calcipotriolandbetamethasonedipropionatecreambasedonpadtechnologyforthetreatmentofplaquepsoriasisanarrativereview AT galvanjordi calcipotriolandbetamethasonedipropionatecreambasedonpadtechnologyforthetreatmentofplaquepsoriasisanarrativereview AT crutchleynigel calcipotriolandbetamethasonedipropionatecreambasedonpadtechnologyforthetreatmentofplaquepsoriasisanarrativereview AT praestegaardmorten calcipotriolandbetamethasonedipropionatecreambasedonpadtechnologyforthetreatmentofplaquepsoriasisanarrativereview AT iversenlars calcipotriolandbetamethasonedipropionatecreambasedonpadtechnologyforthetreatmentofplaquepsoriasisanarrativereview AT gisondipaolo calcipotriolandbetamethasonedipropionatecreambasedonpadtechnologyforthetreatmentofplaquepsoriasisanarrativereview AT carrascosajosemanuel calcipotriolandbetamethasonedipropionatecreambasedonpadtechnologyforthetreatmentofplaquepsoriasisanarrativereview AT haliouabruno calcipotriolandbetamethasonedipropionatecreambasedonpadtechnologyforthetreatmentofplaquepsoriasisanarrativereview AT bewleyanthony calcipotriolandbetamethasonedipropionatecreambasedonpadtechnologyforthetreatmentofplaquepsoriasisanarrativereview AT pinterandreas calcipotriolandbetamethasonedipropionatecreambasedonpadtechnologyforthetreatmentofplaquepsoriasisanarrativereview |